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Pharmacokinetic and behavioral characterization of a longterm
antipsychotic delivery system in rodents and rabbits
Abstract
Rationale: Non-adherence with medication remains the major correctable cause of poor outcome in
schizophrenia. However, few treatments have addressed this major determinant of outcome with novel long-
term delivery systems.
Objectives: The aim of this study was to provide biological proof of concept for a long-term implantable
antipsychotic delivery system in rodents and rabbits.
Materials and methods: Implantable formulations of haloperidol were created using biodegradable polymers.
Implants were characterized for in vitro release and in vivo behavior using prepulse inhibition of startle in rats
and mice, as well as pharmacokinetics in rabbits.
Results: Behavioral measures demonstrate the effectiveness of haloperidol implants delivering 1 mg/kg in mice
and 0.6 mg/kg in rats to block amphetamine (10 mg/kg) in mice or apomorphine (0.5 mg/kg) in rats.
Additionally, we demonstrate the pattern of release from single polymer implants for 1 year in rabbits.
Conclusions: The current study suggests that implantable formulations are a viable approach to providing long-
term delivery of antipsychotic medications in vivo using animal models of behavior and pharmacokinetics. In
contrast to depot formulations, implantable formulations could last 6 months or longer. Additionally, implants
can be removed throughout the delivery interval, offering a degree of reversibility not available with depot
formulations.
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Abstract
Rationale Non-adherence with medication remains the major
correctable cause of poor outcome in schizophrenia. However,
few treatments have addressed this major determinant of
outcome with novel long-term delivery systems.
Objectives The aim of this study was to provide biological
proof of concept for a long-term implantable antipsychotic
delivery system in rodents and rabbits.
Materials and methods Implantable formulations of halo-
peridol were created using biodegradable polymers.
Implants were characterized for in vitro release and in vivo
behavior using prepulse inhibition of startle in rats and
mice, as well as pharmacokinetics in rabbits.
Results Behavioral measures demonstrate the effectiveness
of haloperidol implants delivering 1 mg/kg in mice and
0.6 mg/kg in rats to block amphetamine (10 mg/kg) in mice
or apomorphine (0.5 mg/kg) in rats. Additionally, we
demonstrate the pattern of release from single polymer
implants for 1 year in rabbits.
Conclusions The current study suggests that implantable
formulations are a viable approach to providing long-term
delivery of antipsychotic medications in vivo using animal
models of behavior and pharmacokinetics. In contrast to
depot formulations, implantable formulations could last
6 months or longer. Additionally, implants can be removed
throughout the delivery interval, offering a degree of
reversibility not available with depot formulations.
Keywords Antipsychotic agents . Treatment adherence .
Schizophrenia . Drug delivery systems . Drug implants .
Prepulse inhibition . Haloperidol . Rat . Mouse . Rabbit
Introduction
Non-adherence with prescribed therapeutics remains the
highest predictor of patient relapse and rehospitalization
(Ayuso-Gutierrez and del Rio Vega 1997; Harris et al.
2002; Lieberman et al. 2005; Olfson et al. 2000; Svarstad et
al. 2001). Up to 55% of individuals with schizophrenia
have significant difficulties adhering to treatment (Corriss
et al. 1999). Non-adherent patients are twice as likely to
undergo rehospitalization from relapse (Svarstad et al.
2001), resulting in a poor quality of life. A Medicaid study
found that only 11.6% of treated patients achieved 1 year of
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uninterrupted antipsychotic medication therapy (McCombs
et al. 1999). Economically, the social burden of healthcare
costs for non-adherence in mental illnesses like schizophre-
nia has been estimated at $2.3 billion annually (Menzin et
al. 2003). Another study found an actual medicine
adherence rate of 23% to be in stark contrast with a
patient-reported rate of 55%, a larger than twofold
difference (Velligan et al. 2003), suggesting that non-
adherence is a greater problem than previously thought.
There are multiple causes of non-adherence in schizo-
phrenia ranging from adverse drug side effects to lack of
family support (Robinson et al. 2002), but previous aims at
improving adherence through parenteral administrations of
antipsychotic agents have proven effective. Depot injec-
tions, in particular, have worked well to deliver antipsy-
chotic medications over long periods of time with enhanced
efficacy over oral dosing (Adams et al. 2001; Gastpar et al.
2005). However, limitations of depot formulations restrict
more significant improvements in adherence and efficacy.
For example, adverse side effects are occasionally man-
ifested and must be endured for the remainder of the
treatment interval due to the inability to remove depot
medications. Prolonged pain often persists at repeated
injection sites and as a result, many patients cease to return
for continued clinical treatment (Kane et al. 1998).
Decanoate formulations are further limited by chemistry,
with many compounds unable to form the required ester
linkages. Although studies demonstrate promising results
with risperidone depots over the course of 1 year of
treatment (Martin et al. 2003), injections must be adminis-
tered bimonthly, requiring 24 annual treatment decisions by
patients, and therefore may not provide adequate sustained
care to many patients with schizophrenia.
Accordingly, we have investigated a new method of
long-term implantable medication delivery to improve
adherence in the treatment of schizophrenia. Implantable
systems have the capability to optimize a medication’s
therapeutic properties, rendering treatments that are more
safe, efficacious, and reliable (Dash and Cudworth 1998).
The gastrointestinal tract is bypassed; therefore, less
medication is generally required, and side effects can be
minimized. Implantable systems can also be easily removed
in case of adverse side effects, offering a degree of
reversibility not available with depot injections. With
biodegradable systems advancing further in the field of
drug delivery, required removal surgery is eliminated,
cutting in half the inherent invasiveness to the patient
(Fischel-Ghodsian and Newton 1993).
Many biodegradable implant systems rely on a poly-
lactide-co-glycolide (PLGA) polymer which is highly bio-
compatible and physically strong (Kitchell and Wise 1985).
Its degradation products, lactic acid and glycolic acid, are
water soluble, non-toxic products of normal metabolism that
are either excreted or further metabolized to carbon dioxide
and water in the Krebs (citric acid) cycle (Curtis 1983;
Okada and Toguchi 1995). A limited number of systems
already utilize PLGA and other biocompatible polymers to
successfully achieve long-term delivery, including devices to
control thyrotropin-releasing hormone in controlling metab-
olism (Okada and Toguchi 1995), L-dopa to treat Parkinson’s
disease (Sabel et al. 1990), and naltrexone to treat narcotic
addiction (Sharon and Wise 1981). Several intraocular
systems, including Vitrasert® (Bausch and Lomb), offer
biocompatible delivery systems with controlled-release drug
therapy for periods ranging from several days to 1 year.
The current report provides proof of concept for this new
method of drug delivery in psychiatry rather than an
introduction of a specific product. Additionally, this
research is sponsored by the Stanley Medical Research
Institute, had no support from industry, and thus, has no
inherent limitations regarding future application to a broad
array of compounds. Therefore, we have applied this
technology to the high potency agent haloperidol to
minimize the size of implant needed for effectiveness. The
current study examines in vitro and in vivo kinetics as well
as behavioral testing to determine the viability of the
implantable system.
Materials and methods
In vitro release studies
Implants were fabricated from a PLGA Medisorb® bio-
absorbable polymer (Alkermes, Cincinnati, OH) and halo-
peridol (Sigma, St. Louis, MO). The polymer was
composed of PLGA in a molar ratio of 50:50. Polymer
and drug were mixed in a ratio of 80:20 by mass and
solvent cast. The preparation was evaporated at 40°C in a
vacuum oven under light airflow until no solvent remained
and the mixture had returned to its constituent mass. The
resulting film was compression molded under a force of
25,000 lbs at 80°C for 3 min. Negative control implants
with 0% drug load were fabricated in the same manner.
Each implant was added to a separate amber-glass
dissolution jar (Wheaton, Millville, NJ) containing 500 ml
phosphate-buffered saline solution at pH 7.4. The jars were
stored in the dark at 37.4°C on a shaker at 40 rpm to mimic
biological conditions. Aliquots of 1 ml were taken from
each jar three times per week and analyzed by ultraviolet
spectrophotometry (Hitachi, Los Angeles, CA). Standard
curves were prepared for each drug in phosphate-buffered
saline. Peak absorbency of 249 nm was determined before
analysis. Assays included negative controls at every time
point and a 20-μg/ml positive control of drug in phosphate-
buffered saline to assess stability over time.
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In vivo studies
The Institutional Animal Care and Uses Committee
(IACUC) at the University of Pennsylvania or University
of California at San Diego approved all protocols, and
animals were housed in Association for Assessment and
Accreditation of Laboratory Animal Care (AAALAC)-
accredited animal facilities.
Behavioral studies in mice (conducted at University of
Pennsylvania) The behavioral effects of haloperidol
implants were tested using prepulse inhibition (PPI) of
startle in 32 C57BL/6J mice (Jackson Laboratory, Bar
Harbor, ME). Implants were fabricated as described above
and were designed to deliver 1 mg/kg/day (Siegel et al.
2002). PLGA-haloperidol implants fabricated with this
method have been shown to yield serum concentration of
8.2 nmol/l (3.1 ng/ml) in mice (Talbot et al. 2004). This
concentration is comparable to the haloperidol concentra-
tion in humans that yields 75% D2 receptor occupancy
(7.3 nmol/l, 2.75 ng/ml), suggesting that the behavioral
effects of implants were tested at clinically relevant receptor
occupancy (Regenthal et al. 1997).
Implants were placed in the subcutaneous space on the
dorsal surface under isoflurane anesthesia (Fig. 1). Animals
received either haloperidol (n=16) or blank implants (n=16).
Mice were then tested at 21 days after implantation using
previously described protocols for PPI (Gould et al. 2004).
Each animal was tested after an injection of either vehicle
(n=16) or D-amphetamine (Sigma) 10 mg/kg i.p. (n=16),
resulting in eight animals in each of the four conditions.
Analyses were performed using a between-groups design.
Each trial started with a 5-min acclimation period with a
65-dB acoustic background noise followed by a train of
five 120-dB startle pulses in an effort to make subsequent
startle trials less variable. Startle trials consisted of 40-ms
pulses at 0 (no stimulus), 90, 95, 100, 105, 110, 115, and
120 dB. Each stimulus was presented five times in a
randomized order with an intertrial interval randomized
from 10–20 s. Startle trials were followed by PPI trials.
Each prepulse was 20 ms in duration followed by a 40-ms
startle stimulus of 120 dB. There was a 100-ms interstimulus
interval between prepulse and startle stimuli presentation. PPI
was recorded for prepulse intensities of 69, 73, and 81 dB and
no stimulus. Each prepulse trial was administered five times in
a random order. Data were collected as 60 1-ms voltage
readings, which were averaged over the collection interval to
give an average measure for each trial. The entire session in
mice lasted 25 min.
Behavioral studies in rats (conducted at University of
California, San Diego) A total of 52 rats were utilized in
this study. Implants were designed to release 0.6 mg kg−1
day−1 of haloperidol (Sigma). Subcutaneous implantation of
drug (n=31) or control (n=21) implants was performed
under isoflurane anesthesia. Serum haloperidol levels were
determined using 20 adult male rats with haloperidol
implants on days 14 (n=10), 21 (n=5), and 28 (n=5) and
an additional ten adult male rats with control implants on
days 14 (n=4), 21 (n=3), and 28 (n=3). The behavioral
effects of haloperidol implants were tested using PPI in an
additional 22 adult male Sprague Dawley rats (Harlan
Laboratories, San Diego), weighing 250–350 g, using
previously described methods for this species (Swerdlow
and Geyer 1998). Seven or 14 days after surgery, rats were
exposed to a brief “matching” startle session. Rats were
placed in a startle chamber (SR-LAB; San Diego Instru-
ments, San Diego, CA) and exposed to 5 min of 70-dB
background noise followed by 17 pulse trials of 40 ms 120-
dB noise bursts (pulse) and three prepulse + pulse trials
consisting of a 20 ms 82-dB (12 dB above background)
prepulse followed 100 ms by a 120-dB pulse (onset to
onset). Data from this session were used to assign rats to
balanced dose groups according to their average %PPI.
Behavioral testing continued 2 days after the matching
session. Apomorphine (APO; Sigma) at a dose of 0.5 mg/kg
s.c. or 0.1% ascorbate/saline vehicle was administered to
rats immediately before testing. The test session lasted
19 min and was used to assess the effects of haloperidol
implants on the PPI-disruptive effects of APO. The session
Fig. 1 Insertion of a rod-shaped
PLGA implant into the subcuta-
neous dorsal space of the
mouse. a The implant is placed
in the subcutaneous space of a
mouse through a 4-mm hole. A
1-cm rod before implantation is
displayed in the insert. b An
implant is shown in situ after
closing with a single stitch.
c The mouse shows no signs
of distress in its home cage
10 min after implantation
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consisted of 5 min of 70-dB background followed by five
trial types: pulse noise bursts, prepulse + pulse trials (20-ms
noise bursts 5, 10, or 15 dB above background followed
100 ms by a pulse) and no stimulus (nostim) trials. The
session consisted of initial and final blocks of four pulse
trials separated by two blocks that included eight pulse trials
and 15 prepulse + pulse trials (the latter divided equally
among 5, 10, and 15-dB prepulse intensities); nostim trials
were interspersed between all trials. For these “nostim”
trials, stabilimeter readings were recorded during periods
where no stimulus was presented; these trials were used to
assess gross motor activity during the test session but were
not included in the calculation of intertrial intervals, which
were variable and averaged 15 s. Four days later, testing was
repeated, with each rat receiving either vehicle or APO. To
understand the effectiveness of the implants over time, one
group of rats was “matched” 1 week post-surgery, and the
other group was matched at 2 weeks. All subsequent testing
was completed in the same timeline.
For comparison to sustained release implants, the PPI-
disruptive effects of APO were also assessed in separate rats
treated with acute haloperidol. APO (0.5 mg/kg s.c.) or 0.1%
ascorbate/saline vehicle was administered to 16 rats 10 min
after injection of haloperidol (Novaplus, Bedford Laborato-
ries, Bedford, OH; 0.1 mg/kg s.c.) or lactic acid/saline
vehicle. Testing was otherwise identical to that completed
with rats that had received sustained-release implants.
Data analysis PPI was calculated as a percent reduction in
startle magnitude on prepulse + pulse trials compared to
pulse trials. Raw startle data were also analyzed to verify
that changes in %PPI reflected changes in the startle-
inhibiting effects of prepulses. Data in rats were analyzed
using repeated measures analysis of variance (ANOVA)
with implantation/pretreatment and implant interval (9 or
16 days) as between-subject factors, and APO, block, and
trial type as within-subject repeated measures. In mice,
startle units and %PPI were analyzed using repeated
measures ANOVA for overall effect and one-way ANOVA
at each decibel intensity. Significant interactions of p<0.05
were further explored using Fisher least significant differ-
ences post-hoc analyses.
Pharmacokinetic studies in rabbits Rabbits (n=6, Covance
Research Products, Denver, PA) ranged in size from
4.0 to 5.7 kg. Five animals received poly-lactide (PLA)-
haloperidol implants designed to deliver 1 mg kg−1 day−1
for an anticipated delivery period of 1 year. One rabbit
received implants of PLA without drug as a negative
control. Rabbits were anesthetized with ketamine/xylazine
(35:5 mg/kg) before s.c. implantation.
Rabbits were vasodilated with acepromazine (1 mg/kg)
twice per month for 12 months to draw 5-ml blood samples
from the ear. Whole blood was centrifuged, and haloperidol
was extracted from serum with an Oasis MCX solid phase
extraction column (Waters, Milford, MA). Analysis was
performed by HPLC with UV detection at 254 nm. A
standard curve for the assay was made with extracted serum,
and the retention time for haloperidol was determined from
positive control samples within each run. The positive
control condition consisted of haloperidol spiked in serum
as well as haloperidol in mobile phase. Negative controls
were also assayed at each time point. Rabbits were sacrificed
after 365 days and the remains of implants removed.
Constituents of residual implants were determined by 1H
NMR. Nuclear magnetic resonance (NMR) was performed
at 25°C on a Varian Unity Inova 300 MHz instrument, and
spectra were analyzed using VNMR 6.1b software (Varian,
Palo Alto, CA). Control samples of PLA (Alkermes 100DL
High IV) and haloperidol were run in dimethyl sulfoxide
(DMSO) and chloroform to define peaks of interest for each
compound. Implants were initially dissolved in DMSO-d6,
and residual solids were then removed by filtration and
dissolved in CDCl3 (chloroform).
Results
In vitro release studies
The pattern of in vitro drug release from single-polymer
implants is shown in Fig. 2a with data expressed as percent
total drug content. Full release for 50:50 PLGA implants,
similar to those used in behavioral studies in mice, was
reached at 40 days. The pattern was characterized by a
period of relatively slow release for the first 10 days. This
was followed by a steady, more rapid release until day 35
and another slow release period until the implant was
depleted. Figure 2b demonstrates the appearance of disc-
shaped haloperidol implants over the delivery interval with
the implant swelling as it becomes hydrated and growing
smaller as the polymer is degraded and drug is released.
Note that the entire drug load is released before total
disintegration of the implant, suggesting that reversibility of
the procedure is retained throughout the delivery interval.
Behavioral studies
Mouse Haloperidol implants were tested using amphetamine-
induced disruption of PPI and startle in mice. There was an
overall effect of drug condition on acoustic startle response
[F(3,25)=3.61, p=0.027] and a significant interaction between
condition and dB intensity [F(21,175)=2.86, p<0.001]
(Fig. 3b). Post-hoc analyses showed that D-amphetamine
decreased startle in control implant mice at the four highest
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intensities (105, 110, 115, and 120 dB). This effect was
blocked by haloperidol implants at 105, 110, and 120 dB.
Additionally, startle response in haloperidol implant mice after
amphetamine was not significantly different than control
implant mice after saline. Repeated measures ANOVA
revealed a marginally significant effect of drug treatments
(all implant and injection conditions) for PPI [F(3,25)=2.89,
p=0.055] as well as a significant interaction between
treatment conditions and prepulse intensity [F(6,50)=2.41,
p=0.040] (Fig. 3a). Post-hoc analyses showed that
D-amphetamine (10 mg/kg) reduced PPI at 81 dB in control
animals (p=0.018) and that haloperidol implants reversed
this effect (haloperidol implant with amphetamine vs
control implant with amphetamine, p<0.001).
Rat Haloperidol serum levels from implants were 2.3±
0.25 ng/ml at 14 days (n=10), 1.9±0.21 ng/ml at 21 days
(n=5), and 0.11±0.05 ng/ml at 28 days (n=5). Therefore,
PPI and startle experiments in rat were performed before
21 days to ensure appropriate serum concentration. Haloper-
idol implants significantly attenuated the PPI-disruptive
effects of APO (Fig. 4a and b). ANOVA of raw startle
magnitude revealed significant main effects of APO [F(1,18)=
19.91, p<0.001] and trial type [F(3,54)=38.00, p<0.001],
two-way interactions of APO by trial type [F(3,54)=6.01,
p=0.001] and haloperidol implant by trial type [F(3,54)=
7.35, p<0.001], and a three-way interaction of implant by
APO by trial type [F(3,54)=5.94, p=0.001]. There were no
significant effects of post-implant test interval (9 or 16 days)
on raw startle magnitude. Inspection of the data (Fig. 4a)
reveals the APO-induced loss of the startle-inhibiting effects
of prepulses in rats with control implants (left side of figure)
and the restoration of these startle-inhibiting effects in rats
with haloperidol implants (right side of figure).
ANOVA of PPI revealed significant main effects of
APO [F(1,18)=127.04, p<0.001], haloperidol implant
[F(1,18)=33.42, p<0.001], and prepulse intensity [F(2,36)=
43.51, p<0.001] along with a significant APO by implant
condition interaction [F(1,18)=38.39, p<0.001]. There
were no significant effects of post-implant test interval
(9 or 16 days) on PPI. Because there was a significant
implant condition by APO interaction, pair-wise two-way
repeated ANOVA were conducted on the saline and APO-
treated groups separately. Post-hoc comparisons revealed a
significant effect of haloperidol implant in APO-treated
rats [F(1,20)=35.80, p<0.001], but no effect of haloperidol
implant in the saline-treated rats. These effects on PPI
reflected a significant APO-induced loss of the startle-
suppressing effects of prepulses and an opposition of this
effect by haloperidol implants (Fig. 4b). The patterns of
haloperidol effects on PPI in implant groups closely parallel
the results seen with an acute injection of haloperidol as seen
in Fig. 4c. All relevant statistical effects for acute haloperidol
were comparable to those reported above for implanted
haloperidol as follows. ANOVA revealed significant main
effects of haloperidol [F(1,14)=19.58, p<0.001] and APO
[F(1,14)=131.10, p<0.001] and a significant interaction of
haloperidol by APO [F(1,14)=96.48, p<0.001]. Post-hoc
analysis confirmed that the basis for this interaction was the
significant PPI-enhancing effect of haloperidol in APO-
treated rats [F(1,14)=95.47, p<0.001]. There were also
significant effects of prepulse intensity [F(2,28)=42.84,
p<0.001] and a significant three-way interaction of prepulse
intensity by haloperidol by APO [F(2,28)=5.81, p<0.008],
but no other significant two- three- or four-way interactions.
Pharmacokinetic studies in rabbits
Long-term in vivo pharmacokinetic profile from PLA
implants was tested in rabbits to assess the prospect of
creating an annual drug delivery system for schizophrenia
(Fig. 5). The five rabbits implanted with PLA-haloperidol
had detectable serum levels for 360 days with a mean
serum concentration of 6.6±1.1 nmol/l (2.5±0.4 ng/ml).
The data are shown with a trendline to illustrate the pattern
Fig. 2 In vitro release from 20% haloperidol-loaded pellets of 50:50
4A PLGA polymer. a Data are expressed as percent of total drug
released and indicate a slow onset followed by a period of steady rapid
release, slowing again to a full release at 40 days. b Photographs of a
haloperidol-loaded pellet over 49 days of release show that the
implant first swelled as it hydrated and then shrank as drug was
released
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of serum concentration over time. This trendline, which
describes the data with a correlation coefficient (R2) of
0.86, has an approximately symmetrical pattern with
maximum values at approximately the T1/2 for this implant
system (6 months). This pattern suggests that a new set of
implants could be added every 6 months to oscillate around
a desired steady state concentration.
Analyses of residual implant material
No local tissue reaction, fibrosis, or irritation was observed
upon implant removal, suggesting good local biocompati-
bility and reversibility throughout the delivery interval.
Residual implants were analyzed using both NMR and
HPLC to determine the presence of PLA and haloperidol at
the time of removal. HPLC/UV and NMR spectroscopy
confirmed the presence of haloperidol and PLGA break-
down products in residual implants. All expected haloper-
idol peaks were present in DMSO as demonstrated in Fig. 6.
Additionally, there were small peaks from 5.2–5.4 ppm that
were indicative of the –CH peak in PLA. However, the
corresponding –CH3 peaks from PLA would have been
obscured by the haloperidol peaks at low polymer concen-
trations. The CDCl3 sample contained characteristic haloper-
idol peaks at 8.1 and 7.4 ppm, but did not have the same
magnitude of haloperidol peaks as the DMSO sample
presumably because most of the haloperidol was extracted
in DMSO. The chloroform fraction contained peaks at 0.9,
1.2, 3.9, and 4.5, consistent with lactic acid, the degradation
product of PLA (Fig. 6).
Discussion
This study demonstrates in vitro and in vivo proof of
concept for antipsychotic implants based on biodegradable
PLGA copolymers. The results suggest that implantable
systems with antipsychotic medications could achieve
medication onset within 2 weeks and could be tailored to
last up to 6 months according to the needs of the patient.
Fig. 3 Behavioral results in
implanted mice. Haloperidol
implants attenuated amphet-
amine-induced reduction in
startle (a) and PPI (b) in mice.
Asterisk indicates p<0.05 dif-
ference from control implant
mice with saline injection. Tau
indicates p<0.05 difference
from control implant mice with
amphetamine injection
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Furthermore, the procedure for implantation (and removal,
if necessary) could be performed in a short amount of time
in an outpatient setting and could be easily tolerated with
local anesthetic before subcutaneous insertion. Additional-
ly, many medications that may be limited by chemistry in
forming long-lasting decanoates could be incorporated into
implantable systems using a variety of polymer matrices.
PPI deficits seen in schizophrenia patients can be
modeled using dopamine agonists such as amphetamine
and apomorphine. However, acute antipsychotic effects that
are often used to reverse these deficits in animal models do
not effectively model the steady-state condition achieved in
humans, especially due to a short half-life of many drugs in
rodents. Mini-pumps are often used to overcome this
problem and provide chronic infusion of drug. However,
the inability to place relatively large mini-pumps in humans
has limited the capacity to have a model that is directly
translatable to human use. Alternatively, biodegradable
PLGA implants provide a method that can be adapted
directly to human use.
In the current study, functional measures of antipsychotic
implants were examined using PPI in two species of rodent.
Haloperidol implants blocked amphetamine-induced reduc-
tions in PPI and startle inmice. Similarly, haloperidol implants
blocked apomorphine-induced reductions in PPI in rats,
comparable to the effects of acute haloperidol injection. These
results indicate that haloperidol implants are effective in this
animal model of information processing deficits in schizo-
phrenia, across laboratories, methods, and species.
Long-term pharmacokinetics of haloperidol implants
were tested in rabbits over a 1-year period. As evidenced
by Fig. 5, the trendline that describes the data for PLA-
haloperidol implanted rabbits (R2=0.86) has a symmetrical
pattern with maximum values at approximately 6 months.
All negative controls resulted in no drug detected (data not
shown). The coherence of polymer implants over time was
validated, with the removal of implants occurring at
Fig. 5 In vivo haloperidol release from polymer-based implant
system in rabbit. Blood samples were evaluated by HPLC for
haloperidol concentration. Release is expressed as haloperidol level
in nanograms per milliliter. The chart displays data averaged from five
animals with a zero-intercept, sixth-degree polynomial average trend-
line resulting in R2=0.86. The negative control resulted in no drug
detected (data not shown). The five animals that received PLA-
haloperidol implants had a mean haloperidol serum concentration of
2.5±0.4 ng/ml over the course of 360 days
Fig. 4 Haloperidol implants attenuated apomorphine-induced reduc-
tion of startle (a) and PPI (b) in rats. These effects were comparable to
those seen with acute haloperidol injection (c). Asterisk indicates p<
0.05 difference from control implant rats with saline injection. Tau
indicates p<0.05 difference from control implant rats with apomor-
phine injection, P120—startle stimulus alone, PP75—prepulse of
75 dB followed by startle stimulus, PP85—prepulse of 80 dB
followed by startle stimulus, PP85—prepulse of 85 dB followed by
startle stimulus
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365 days after implantation. Observation of implants in
vitro also showed coherence of the implant after drug was
depleted, indicating that removal could be performed if
needed well into the duration of implantation. This is a
major advantage over existing depot medications using
either microspheres (risperidone) or decanoate formulations
(haloperidol and fluphenazine).
It is important to note that there are considerable
interspecies differences in the metabolism of many drugs,
including haloperidol, with rabbits requiring approximately
30-fold higher doses than humans for equivalent plasma
concentration. Thus, the absolute doses used in the current
study approximate the amount of drug needed for a human
despite the difference in body mass. As humans require
approximately 50 mg/month of haloperidol when given as a
depot preparation, a 6-month implant system would contain
300 mg of drug. Thus, the implant design used in the
current study would necessitate only 750 mg of total
material with a 40% drug load for 1 year of treatment.
These materials have a specific gravity of 1.2 g/ml2,
potentially yielding three semi-annual implants with a
diameter of 3 mm and length of 3 cm. Reimplantation
every 6 months would result in a gradual escalation to
therapeutic level during the first 6 months, followed by
small oscillations around a desired serum concentration
(Fig. 7a). A series of “starter” polymers with shorter release
period could be used at the time of the first implantation to
bridge the 6-month lag to therapeutic levels (Fig. 7b).
Although the current formulation utilized haloperidol,
other high potency antipsychotic medications including
risperidone also show promise for this approach. Whereas
many studies have extolled the virtues of such newer
agents, recent meta-analyses and controlled clinical trials
have questioned the extent to which newer, more costly
agents add benefit over low-dose traditional agents (Davis
et al. 2003; Geddes et al. 2000; Lieberman et al. 2005;
Rosenheck et al. 2003). Since PLGA implants are amenable
to many compounds, future studies can incorporate various
agents to test their applicability in long-term delivery
implants. The stability of each drug in PLGA polymer
implants will vary, because as the implant is hydrated, the
drug will be exposed to an aqueous environment. There-
fore, drugs such as haloperidol and others that are stable in
aqueous media for greater than 1 year are preferable for
such systems.
There were several limitations to the current study. For
example, the selection of animals that were similar in size
and that live in a controlled environment limits the ability
to fully recreate variances in body mass index, body
temperature, drug metabolism, and implant degradation
rates that would exist in humans. However, implants were
tailored to match animals of approximately 30 g (mouse),
300 g (rat) and 5,000 g (rabbit) showing flexibility over two
orders of magnitude range of body mass. Drug dosing with
implants in a patient population would also need to be
tailored to fit the treatment needs of each patient. Once the
bioequivalence is established between oral, injectable, and
implantable formulations, patients could be dosed based on
known relationships and body mass. Both the size and
number of implants could be varied based on the indicated
Fig. 6 The top 1H NMR control spectrum shows a PLA and 40%
(w/w) haloperidol mixture in DMSO-d6. Also depicted are the
corresponding chemical structures of haloperidol and PLA. The
middle spectrum shows rabbit sample in DMSO-d6 with peaks
corresponding to those seen in the control spectrum. The bottom
picture shows rabbit sample in chloroform with peaks at 0.9, 1.2, 3.9,
and 4.5 consistent with the degradation product of PLA, lactic acid
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dose for that person. For example, modular systems for 0.5
and 1.0 mg/day could be offered to customize implants using
these doses alone or in combination (i.e., 1.5 mg/day could
be made by combining 1.0 and 0.5 mg/day sets). The current
study shows that long-term in vivo release of haloperidol
from biodegradable implants is viable for a dosing interval of
2 weeks to 6 months. However, extension of long-term
delivery to other medications and medical conditions is
desirable. The use of implants to treat psychiatric or non-
psychiatric disorders would necessarily require safeguards to
ensure patients’ ability to provide informed consent. Al-
though minimally invasive, the procedures for implantation
and possible removal still necessitate careful attention to
protect patient autonomy. Consistent with this goal, one
advantage of surgically implantable systems would be that
patients could make decisions regarding long-term treatment
during periods of health. After medication treatment, patients
are able to achieve significant symptom remission such that
they could make decisions to follow long-term medication
treatments for the subsequent 6 to 12 months. Previously
published and preliminary data from our group suggest that
many patients (43%) and their families (70%) would support
such surgically implantable, long-term methods of treatment
if they were available (Irani et al. 2004; Dankert et al., in
review).
Whereas many studies report medication adherence rates
of 50%, it is increasingly thought that data are skewed, as
many patients cease medication treatment once outside
clinical trials (Seeman 2001). However, when the physician
and patient come to a consensus regarding implantable
medication, the treatment plan could be implemented in
15 min during the same outpatient visit. This would require
only one procedure semi-annually, rather than the 6
(decanoate) to 12 (microsphere) necessary for depot
injections. Consequently, it is important to note that
although implants would provide improved convenience
and access to medication, they would not replace the need
for patients to interact with psychiatrists and therapists.
Rather, improved medication adherence and continuous
access to medication would allow patients and their
physicians to focus on issues other than medication
adherence in the service of a more comprehensive treatment
plan.
As the desire has increased for long-term delivery of
medication to treat countless chronic illnesses, it is also
beneficial to explore sustained delivery options for a variety
of pharmaceuticals, especially those that are limited by the
chemistry of decanoates. A need for lasting medication
systems has already been expressed in several fields,
including treatments for cardiovascular disease (Chui et al.
2003), diabetes (Boccuzzi et al. 2001), cancer (Natsugoe et
al. 1997) and HIV/AIDS (Andrews and Friedland 2000;
Melbourne et al. 1999; Tucker et al. 2003). Accordingly,
the ability of surgically implantable long-term delivery
systems to incorporate other medications for the treatment
of psychiatric and non-psychiatric illnesses has been further
explored in complimentary studies associated with our
group (Siegel et al. 2006).
In summary, we advocate the use of long-term surgically
implantable formulations of antipsychotic medications for
improved adherence in the treatment of psychotic disorders.
This study demonstrates the behavioral and pharmacoki-
netic feasibility of such a system allowing release for up to
one year. Further in vivo and in vitro trials of implantable
formulations with a variety of medications could be
examined to utilize other antipsychotic agents and treat a
large number of chronic disorders.
Fig. 7 Representation of ideal multiple polymer-antipsychotic im-
plant system. a Combined release (dark solid line) following
reimplantation of a single polymer every 6 months (gray dotted
lines). Note that this system would result in a gradual escalation to
therapeutic level during the first 6 months followed by small
oscillations around a desired serum concentration. b Representation
of a five-polymer system in which four rapidly degrading polymers
(starter set) are combined with one longer lasting polymer (mainte-
nance set) that is reimplanted every 6 months. Levels that result from
all five individual polymers are represented with the solid line, and
release profiles from individual polymers are represented by dashed
lines. This system could reach target levels in approximately 2 weeks
with small oscillations around a target concentration thereafter
Psychopharmacology
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